Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD) [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
transaction was executed at a price of $13.35 per share, resulting in a total sale amount of $200,250.Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. The company's lead product is a platform of enzyme replacement therapies for the treatment of lysosomal storage disorders, a group of rare, inherited metabolic disorders.Over the past year, the insider has engaged in the sale of 15,000 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a broader trend observed over the past year, where there have been no insider buys and 52 insider sells for Amicus Therapeutics Inc. On the valuation front, shares of Amicus Therapeutics Inc were trading at $13.35 on the day of the insider's sale, giving the company a market capitalization of $3.721 billion. The stock's price-to-GF-Value ratio stands at 0.93, indicating tha
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? [Yahoo! Finance]Yahoo! Finance
- Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportGlobeNewswire
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.MarketBeat
FOLD
Earnings
- 2/28/24 - Beat
FOLD
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- FOLD's page on the SEC website